https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21643 Wed 11 Apr 2018 11:01:30 AEST ]]> Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18606 Sat 24 Mar 2018 08:01:03 AEDT ]]>